Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +
02:15pm, Friday, 19'th Jul 2024
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt ra
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
09:45am, Wednesday, 17'th Jul 2024
Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
04:37pm, Monday, 24'th Jun 2024
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
07:00am, Friday, 21'st Jun 2024
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.
07:00am, Monday, 17'th Jun 2024
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced
Arvinas to Participate in Upcoming Investor Conferences
04:30pm, Monday, 03'rd Jun 2024
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
05:00pm, Thursday, 23'rd May 2024
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 cli
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
06:00am, Thursday, 16'th May 2024
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combina
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Tuesday, 07'th May 2024
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Tuesday, 07'th May 2024
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study le
Why Earnings Season Could Be Great for Arvinas (ARVN)
11:01am, Thursday, 02'nd May 2024
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 01'st May 2024
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Friday, 26'th Apr 2024
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
